Download Announcement of Guest Plenary Speaker at The APS

'Pharmaceutical Sciences: Improving World Health'
Monday 5 – Wednesday 7 September 2016 at the Technology and Innovation Centre, University of Strathclyde, Glasgow
Announcement of Guest Plenary Speaker at
The APS International PharmSci Conference 2016
The APS are pleased to announce that Prof Gavin Halbert who is a Director, Cancer Research UK Formulation Unit,
Strathclyde Institute of Pharmacy and Biomedical Sciences, will be delivering a plenary lecture on Wednesday 7 September
2016.
Gavin’s talk is entitled ‘The Impact of Cancer Chemotherapy on Formulation, Manufacture and Supply’.
Over the past two decades cancer chemotherapy has been revolutionised by developments in
molecular biology which have permitted the targeting of specific molecular defects. The
physicochemical properties of anti-cancer drugs have therefore dramatically changed and this
has impacted on the formulations required to deliver effective therapy. In addition targeted
therapy is presenting future challenges related to the supply and distribution of products to
specific patient groups. These developments will be explored through the role of the Cancer
Research UK Formulation Unit.
Prof Halbert is a pharmacist and chemist (University of Strathclyde 1979) with a PhD in
Physiochemical Aspects of Anti-Cancer Drug Targeting Systems (University of Strathclyde 1984).
He was appointed as a lecturer in pharmaceutical sciences at University of Strathclyde in 1984
and Director of the Cancer Research UK Formulation Unit in 1992. The Unit's role is to
characterise, analyse, formulate and manufacture putative anti-cancer drugs accepted by Cancer
Research UK’s New Agents Committee for use in human clinical trials. Personal experience of pharmaceutically progressing
over 30 novel NCEs into clinical trials, including agents such as temozolomide and abiraterone acetate. Research interests
include medicinal and analytical chemistry, drug physiochemistry, formulation for both parenteral and oral products and the
GMP production of specialist pharmaceutical products for phase l clinical trials. The latter incorporates research areas such
as microbiology and lyophilisation. Related research is also conducted in drug targeting and delivery systems for cancer
chemotherapy for example the utilisation of synthetic Low Density Lipoprotein systems and the biopharmaceutical
assessment of new formulations.
Other confirmed Plenary speakers:
•
•
Prof Kay Marshal, University of Manchester - winner of the APS Award (sponsored by AstraZeneca)
Prof Christine Allen- Faculty of Pharmacy at the University of Toronto - The Promise of Nanotechnology in
Oncology: The Time is Now.
For more information on the conference, and to submit an abstract please visit the Conference Website regularly to keep
updated on further announcements.
Register at http://www.ukpharmsci.org/ on or before 31 July 2016
to take advantage of the Early Bird Rates for the conference
7th International PharmSci Conference 2016 is grateful for the support of our sponsors: